Inclusion criteria for patients with Alzheimer's disease (AD):

• Age between 50 and 90 years.
• Diagnosis of Alzheimer's disease according to established diagnostic criteria.
• Mini-Mental State Examination (MMSE) score between 18 and 24.
• Stable pharmacological treatment for at least 3 months before enrolment.
• Ability and willingness to provide written informed consent.

Inclusion criteria for caregivers:

• Age ≥18 years.
• Availability to assist the patient throughout the study.
• Ability and willingness to provide written informed consent.

Exclusion criteria for patients with Alzheimer's disease (AD):

• Refusal or inability to provide written informed consent.
• History of psychiatric disorders.
• Significant cerebrovascular disease.
• Severe visual or hearing impairment that could interfere with study procedures.
• Psychosis.
• Major depressive disorder.
• Alcohol or substance abuse.
• Use of psychotropic medications that may interfere with neuropsychological assessment or study treatment.
• Concurrent participation in another interventional pharmacological clinical trial.
• Any contraindication to undergoing EEG recording.

Exclusion criteria for caregivers:

• Refusal or inability to provide written informed consent.
• History of psychiatric disorders.
• Major depressive disorder.
• Alcohol or substance abuse.
• Use of psychotropic medications that may interfere with neuropsychological assessment.